Decreased early atherosclerotic lesions in hypertriglyceridemic mice expressing cholesteryl ester transfer protein transgene

Journal of Clinical Investigation

Volumn 96, Issue 4, 1995, Pages 2071-2074

  Hayek, Tony ^a   Masucci Magoulas, Lori ^b   Jiang, Xian ^b   Walsh, Annemarie ^a   Rubin, Edward ^c   Breslow, Jan L ^a   Tall, Alan R ^b  

^a ROCKEFELLER UNIVERSITY   (United States)

^b Columbia Univ Coll Phys Surgs ^*  (United States)

^c UNIVERSITY OF CALIFORNIA   (United States)

Author keywords

atherosclerosis; cholesteryl ester transfer protein; high density lipoproteins; hypertriglyceridemia; transgenic mouse

Indexed keywords

APOLIPOPROTEIN C3; CHOLESTEROL; CHOLESTEROL ESTER TRANSFER PROTEIN; TRIACYLGLYCEROL;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; AORTA ATHEROSCLEROSIS; ARTICLE; CHOLESTEROL DIET; CHOLESTEROL TRANSPORT; CONTROLLED STUDY; GENE EXPRESSION; HYPERTRIGLYCERIDEMIA; MOUSE; NONHUMAN; PRIORITY JOURNAL; TRANSGENE; TRANSGENIC MOUSE;

EID: 0028784246     PISSN: 00219738     EISSN: None     Source Type: Journal    
DOI: 10.1172/JCI118255     Document Type: Article

References (31)

1. Morton, R. E., and D. B. Zilversmit. 1983. Inter-relationship of lipid transferred by the lipid-transfer protein isolated from human lipoprotein-deficient plasma. J. Biol. Chem. 258:11751-11757.
2. Albers, J. J., J. H. Tollefson, C. Chen, and A. Steinmetz. 1984. Isolation and characterization of human plasma lipid transfer proteins. Arteriosclerosis. 4:49-58.
3. Tall, A. R. 1986. Plasma lipid transfer proteins. J. Lipid Res. 27:361-367.
4. Inazu, A., M. L. Brown, C. B. Hesler, L. B. Agellon, J. Koizumi, K. Takata, Y. Maruham, H. Mabuchi, and A. R. Tall. 1990. Increased high density lipoprotein levels caused by common cholesteryl-ester transfer protein gene mutation. N. Engl. J. Med. 323:1234-1238.
5. Gordon, D. J., and B. M. Rifkind. 1989. High density lipoprotein: the clinical implications of recent studies. N. Engl. J. Med. 321:1311-1316.
6. Castelli, W. P., R. J. Garrison, P. W. F. Wilson, R. D. Abbott, S. Kulonsdiun, and W. B. Kannel. 1986. Incidence of coronary heart disease and lipoprotein cholesterol levels. J. Am. Med. Assoc. 256:2835-2838.
7. Miller, N. E. 1987. Association of high-density lipoprotein subclasses and apolipoproteins with ischemic heart disease and coronary atherosclerosis. Am. Heart J. 113:589-597.
8. Barter, P. J., G. J. Hopkins, and G. D. Calvert. 1982. Transfers and exchanges of esterified cholesterol between plasma lipoproteins. Biochem. J. 208:1-7.
9. Fielding, P. E., C. J. Fielding, R. J. Havel, J. P. Kane, and P. Tun. 1983. Cholesterol net transport esterification and transfer in human hyperlipidemic plasma. J. Clin. Invest. 71:449-460.
10. 3. J. Biol. Chem. 264:6488-6494.
11. Chajek-Shaul, T., T. Hayek, A. Walsh, and J. L. Breslow. 1991. Human apo A-I expression in transgenic mice alters HDL particle size distribution and diminishes selective uptake of HDL cholesteryl esters. Proc. Natl. Acad. Sci. USA. 88:6731-6735.
12. Rubin, E. M., B. Y. Ishida, S. M. Clift, and R. M. Kraus. 1991. Expression of human apolipoprotein A-I in transgenic mice results in reduced plasma levels of murine apolipoprotein A-I and the appearance of two new high density lipoprotein size subclasses. Proc. Natl. Acad. Sci. USA. 88:434-438.
13. Agellon, L. B., A. Walsh, T. Hayek, P. Moulin, X. L. Jiang, S. A. Shelanski, J. L. Breslow, and A. R. Tall. 1991. Reduced high density lipoprotein cholesterol in human cholesteryl ester transfer protein transgenic mice. J. Biol. Chem. 266:10796-10801.
14. Hayek, T., T. Chajek-Shaul, A. Walsh, L. B. Agellon, P. Moulin, A. R. Tall, and J. L. Breslow. 1992. An interaction between the human cholesteryl ester transfer protein (CETP) and apolipoprotein A-I genes in transgenic mice results in a profound CETP-mediated depression of high density lipoprotein cholesterol levels. J. Clin. Invest. 90:505-510.
15. Hayek, T., N. Azrolan, R. B. Verdery, A. Walsh, T. Chajek-Shaul, L. B. Agellon, A. R. Tall, and J. L. Breslow. 1993. Hypertriglyceridemia and cholesteryl ester transfer interact to dramatically alter high density lipoprotein levels, particle sizes and metabolism. J. Clin. Invest. 92:1143-1152.
16. Aalto-Setala, K., E. A. Fisher, X. Chen, T. Chajek-Shaul, T. Hayek, R. Zechner, A. Walsh, R. Ramakrishnan, H. N. Ginsberg, and J. L. Breslow. 1992. Mechanism of hypertriglyceridemia in human apo CIII transgenic mice: diminished fractional catabolic rate associated with increased apo CIII and reduced apo E on the particles. J. Clin. Invest. 90:1889-1900.
17. Ito, Y., N. Azrolan, A. O'Connell, A. Walsh, and J. L. Breslow. 1990. Hypertriglyceridemia as a result of human apo CIII gene expression in transgenic mice. Science (Wash. DC). 249:790-793.
18. Walsh, A., N. Azrolan, K. Wang, A. Marcigliano, A. O'Connell, and J. L. Breslow. 1993. Intestinal expression of the human apo A-I gene in transgenic mice is controlled by a DNA region 3′ to the gene in the promoter of the adjacent convergently transcribed apo CIII gene. J. Lipid Res. 34:617-623.
19. Paigen, B., A. Morrow, P. A. Holmes, D. Mitchell, and R. A. Williams. 1987. Quantitative assessment of atherosclerotic lesions in mice. Atherosclerosis. 68:231-240.
20. Rubin, E. M., R. M. Krauss, E. A. Spangler, J. G. Verstuyft, and S. M. Clift. 1991. Inhibition of early atherogenesis in transgenic mice by human apolipoprotein A-I. Nature (Lond.). 353:265-267.
21. Marcel, Y., L. R. McPherson, M. Hogue, H. Czarnecka, Z. Zawudski, P. K. Weech, M. E. Whillock, A. R. Tall, and R. W. Milne. 1990. Distribution and concentration of cholesteryl ester transfer protein in plasma of normolipidemic subjects. J. Clin. Invest. 85:10-12.
22. Plump, A. S., J. D. Smith, T. Hayek, K. Aalto-Setala, A. Walsh, J. G. Verstuyft, E. M. Rubin, and J. L. Breslow. 1992. Severe hypercholesterolemia and atherosclerosis in apolipoprotein E-deficient mice created by homologous recombination in ES cells. Cell. 71:343-353.
23. Marotti, K. R., C. K. Castle, Y. P. Boyle, A. H. Lin, R. W. Murray, and G. W. Melchior. 1993. Severe atherosclerosis in transgenic mice expressing simian cholesteryl ester transfer protein. Nature (Lond.). 364:73-75.
24. Einarsson, K., K. Hellstrom, and M. K. Kallner. 1975. Gallbladder disease in hyperlipoproteinemia. Lancet. i:484-487.
25. Jergenson, T. 1989. Gallstones and plasma lipids in the Danish population. Scand. J. Gastroenterol. 24:916-922.
26. Duane, W. O. 1995. Abnormal bile and absorption in familial hypertriglyceridemia. J. Lipid Res. 36:96-107.
27. Fielding, C. J., and P. E. Fielding. 1995. Molecular physiology of reverse cholesterol transport. J. Lipid Res. 36:211-228.
28. Plump, A. S., C. Scott, and J. L. Breslow. 1995. Human apolipoprotein A-I gene expression raises HDL and suppresses atherosclerosis in apo E deficient mice. Proc. Natl. Acad. Sci. USA. 91:9607-9611.
29. Paszty, C., N. Maeda, J. Verstuft, and E. M. Rubin. 1994. Apolipoprotein AI transgene corrects apolipoprotein E deficiency-induced atherosclerosis in mice. J. Clin. Invest. 94:899-903.
30. Barter, P., and K.-A. Rye. 1994. Cholesteryl ester transfer protein: its role in plasma lipid transport. Clin. Exp. Pharmacol. Physiol. 21:663-672.
31. Yamashita, S., J. Hirano, M. Ishigami, T. Arai, S. Sakai, S. Nazaki, K. Takemura, and Y. Matsuzawa. 1994. Marked hyperalphalipoproteinemia (HALP) due to a combined reduction in cholesteryl ester transfer protein (CETP) and hepatic triglyceride lipase (HTGL) is accompanied by atherosclerotic cardiovascular diseases (ACD). Circulation. 90:I-510.